BioDuro Completes Acquisition of Molecular Response

BioDuro announced the acquisition of Molecular Response and its translational oncology research platform, including its biobank of more than 100,000 viable tumor specimens. BioDuro customers can now access this platform to support a range of drug discovery oncology and immunooncology studies–from immunophenotyping screens to xenograft pharmacology studies.

BioDuro Completes Acquisition of Molecular Response

The Molecular Response oncology platform comprises the world’s largest collection of viable tumor specimens. These specimens maintain the complexity and heterogeneity of the patient cancer, including tumor, immune and stromal cells, enabling large-scale in vitro and in vivo studies that are otherwise impossible to perform.

“We are committed to growing BioDuro into a complete chemistry and biology provider for our clients, and unique platforms in oncology are a critical centerpiece of that strategy,” said TJ Deng, General Manager for BioDuro Discovery. “The Molecular Response acquisition immediately strengthens our capability and provides our clients a continuous set of capability, enabling our customers to start with our chemistry services through preclinical and translational oncology studies, all the way to IND.”

BioDuro biology maintains an in vivo oncology capability, including 18,000 sq. ft. AAALAC accredited vivarium, cell-derived xenograft (CDX), patient-derived xenograft (PDX), and syngeneic oncology models, with animal imaging and multi-color flow cytometry for immune cell analysis. BioDuro recently launched hTME-3DX Screen and Verify, providing a combination of humanized 3D tumor models in vitro, and follow-on in vivo PDX capability, matched to same primary patient sample.

As part of the acquisition, Molecular Response CEO, Thomas B. Broudy, PhD will assume the role of Executive Vice President, Translational Sciences & Strategy.

BioDuro will maintain Molecular Response as a wholly-owned subsidiary, growing its ongoing operations in Shanghai, Beijing and San Diego with new service offerings using the biobank platform. Molecular Response will continue all business development efforts to sell biospecimens to strategic partners interested in tissue acquisition to support internal capabilities.

  • <<
  • >>